Evidence map›Paper›PMID 25161167›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2014

Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.

Mei-Mei Li, Wei-Peng Wang, Wen-Juan Wu, Min Huang, Ai-Ming Yu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  5. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. RNA therapy: Are we using the right molecules?Pharmacology & therapeutics · 2019
    Review
  16. Article
  17. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.The Journal of pharmacology and experimental therapeutics · 2018
    Article
  18. Article
  19. Upregulated effects of miR-7 in methicillin-resistantExperimental and therapeutic medicine · 2016
    Article
  20. Oscillatory expression inIET systems biology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Mei-Mei LiDepartment of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California (M.-M.L., W.-P.W., W.-J.W., A.-M.Y.); Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China (M.-M.L., M.H.); and Center of Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China (W.-P.W.).
Wei-Peng WangDepartment of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California (M.-M.L., W.-P.W., W.-J.W., A.-M.Y.); Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China (M.-M.L., M.H.); and Center of Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China (W.-P.W.).
Wen-Juan WuDepartment of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California (M.-M.L., W.-P.W., W.-J.W., A.-M.Y.); Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China (M.-M.L., M.H.); and Center of Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China (W.-P.W.).
Min HuangDepartment of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California (M.-M.L., W.-P.W., W.-J.W., A.-M.Y.); Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China (M.-M.L., M.H.); and Center of Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China (W.-P.W.).
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California (M.-M.L., W.-P.W., W.-J.W., A.-M.Y.); Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China (M.-M.L., M.H.); and Center of Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China (W.-P.W.) aimyu@ucdavis.edu.
Soochow University · CNGuangdong Pharmaceutical University · CNSun Yat-sen University · CNUniversity of California Davis Medical Center · US

Funding

MicroRNA-1291 in Regulation of Xenobiotic Disposition and Cell DifferentiationU01CA175315 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2014 to 2018
$1.6M
NCI NIH HHS 1U01-CA17531NCI NIH HHS U01 CA175315
6 · The paper itself

Abstract

Noncoding microRNAs (miRNAs or miRs) have been revealed as critical epigenetic factors in the regulation of various cellular processes, including drug metabolism and disposition. However, research on miRNA functions is limited to the use of synthetic RNA and recombinant DNA agents. Herein, we show that novel pre-miRNA-27b (miR-27b) agents can be biosynthesized in Escherichia coli using recombinant RNA technology, and recombinant transfer RNA (tRNA)/mir-27b chimera was readily purified to a high degree of homogeneity (>95%) using anion-exchange fast protein liquid chromatography. The tRNA-fusion miR-27b was revealed to be processed to mature miRNA miR-27b in human carcinoma LS-180 cells in a dose- and time-dependent manner. Moreover, recombinant tRNA/miR-27b agents were biologically active in reducing the mRNA and protein expression levels of cytochrome P450 3A4 (CYP3A4), which consequently led to lower midazolam 1'-hydroxylase activity. These findings demonstrate that pre-miRNA agents can be produced by recombinant RNA technology for functional studies.

Indexed as

Recombination, GeneticBase SequenceCell Line, TumorChromatography, Ion ExchangeDNA PrimersEscherichia coliHumansMicroRNAsRNADNA PrimersMicroRNAsMIRN27 microRNA, humanRNA

Identifiers

PMID25161167
PMCPMC4201134
OpenAlexW2149992704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.